Visit our Christmas Gift Finder
Biosimilar Clinical Development: Scientific Considerations and New Methodologies - Chapman & Hall/CRC Biostatistics Series (Hardback)
  • Biosimilar Clinical Development: Scientific Considerations and New Methodologies - Chapman & Hall/CRC Biostatistics Series (Hardback)
zoom

Biosimilar Clinical Development: Scientific Considerations and New Methodologies - Chapman & Hall/CRC Biostatistics Series (Hardback)

(editor), (editor), (editor), (editor), (editor)
£80.99
Hardback 248 Pages / Published: 20/12/2016
  • We can order this

Usually dispatched within 2 weeks

  • This item has been added to your basket

Biosimilars have the potential to change the way we think about, identify, and manage health problems. They are already impacting both clinical research and patient care, and this impact will only grow as our understanding and technologies improve. Written by a team of experienced specialists in clinical development, this book discusses various potential drug development strategies, the design and analysis of pharmacokinetics (PK) studies, and the design and analysis of efficacy studies.

Publisher: Apple Academic Press Inc.
ISBN: 9781482231694
Number of pages: 248
Weight: 612 g
Dimensions: 235 x 156 x 15 mm


MEDIA REVIEWS
"Thus, the book Biosimilar Clinical Development contains five chapters discussing general issues involving biosimilars. The remaining six chapters present statistical methods, many of which are new, and their applications in bioequivalence and biosimilarity studies; they are really research papers. . . It will appeal to readers interested in biosimilars and especially in their statistical assessments."
~Laszlo Endrenyi, University of Toronto

"The book is edited by a team of renowned experts from both statistics and biosimilar clinical development. It contains 11 chapters, covering not only statistical issues but also pre-clinical and clinical development issues not regularly discussed on this kind of book, as well as references to regulatory considerations of upmost importance for statisticians working in the strongly regulated environment of clinical development . . . I strongly recommend the reading of this book. In my opinion, the book should be a must-have reading for professionals who work regularly with biosimilars and want to have an overview of state-of-the art methods for 'hot-topics' in the analysis and planning of clinical trials for this purpose."
~David Manteigas

You may also be interested in...

Please sign in to write a review

Your review has been submitted successfully.